Crispr Therapeutics AG of Basel, Switzerland and Cambridge, Massachusetts US has appointed Samarth Kulkarni as its chief business officer to join an expanded leadership team overseeing the company’s gene-editing technology. Dr Kulkarni was previously a partner at McKinsey and Company where he co-led the biotech practice and worked on personalised medicine and immunotherapy. He has a PhD in bioengineering and nanotechnology from the University of Washington.
The new appointments also include Michael Bruce, formerly of Pfizer Inc, who will be overseeing portfolio and alliance management. Dr Bruce received a BA in chemistry from Williams College and a PhD in organic chemistry from Stanford University.
Crispr Therapeutics announced the appointments on 11 August 2015.
Copyright 2015 Evernow Publishing Ltd